Novo Nordisk : files annual report with the SEC

Novo Nordisk files annual report with the SEC

Bagsværd, Denmark, 5 February 2020 - Novo Nordisk A/S has filed its Annual Report 2019 on Form 20-F for the financial year 2019 with the US Securities and Exchange Commission (SEC), incorporating by reference parts of the Novo Nordisk A/S Annual Report 2019. The reports are available at the SEC's website, www.sec.gov, as well as on novonordisk.com.

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products in more than 170 countries. For more information, visit novonordisk.com,Facebook,Twitter,LinkedIn,YouTube.

Further information
Media:
Mette Kruse Danielsen	[phone]	[e-mail]
Ken Inchausti (US)	[phone]	[e-mail]
Investors:
Peter Hugreffe Ankersen	[phone]	[e-mail]
Valdemar Borum Svarrer	[phone]	[e-mail]
Ann Søndermølle Rendbæk	[phone]	[e-mail]
Mark Joseph Root	[phone]	[e-mail]
Kristoffer Due Berg (US)	[phone]	[e-mail]

Novo Nordisk A/S	Novo	Allé	Tel: [phone]	CVR no:
Corporate Communication	2880	Bagsværd	www.novonordisk.com	24 25 67 90
	Denmark